AbCellera Biologics Inc.
ABCLAbCellera Biologics is a clinical-stage biotechnology company that utilizes a proprietary engine to discover and develop next-generation antibody medicines.
Earnings
Next report
Nov 5, 2026 (in 2 months)Financials
Q2 2026Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
AbCellera Biologics is a clinical-stage biotechnology company that utilizes a proprietary engine to discover and develop next-generation antibody medicines. The company focuses on high-value, difficult-to-address targets such as complex transmembrane proteins and multispecific modalities. While originally a service-oriented discovery partner, the company has transitioned toward developing a proprietary internal pipeline of drug assets.
AbCellera maintains a competitive advantage through its specialized platform capable of addressing complex transmembrane proteins and novel antibody modalities.
FAQ
- What is AbCellera Biologics Inc.'s market cap?
- AbCellera Biologics Inc. (ABCL) has a market capitalization of $3.7B and trades on NASDAQ.
- What is AbCellera Biologics Inc.'s revenue and profitability?
- AbCellera Biologics Inc. generated $66.2M in trailing twelve-month revenue with a net loss of $164.7M, representing a net margin of -248.8%. The latest reported period is Q2 2026.
- Who are AbCellera Biologics Inc.'s competitors?
- AbCellera Biologics Inc.'s key competitors include Schrodinger, Absci Corporation Common Stock, Avalo Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is AbCellera Biologics Inc. headquartered?
- AbCellera Biologics Inc. is headquartered in Canada and employs approximately 586 people. It has been publicly traded since 2020.
